Alyeska Investment Group
ALXN

Alyeska Investment Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Alyeska Investment Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-400,000
Closed -$73.5M – 886
2021
Q2 		$73.5M Buy
400,000
+125,000
+45% +$21.5M 0.85% 15
2021
Q1 		$42M Buy
275,000
+175,694
+177% +$27.2M 0.54% 41
2020
Q4 		$15.5M Buy
+99,306
New +$12.8M 0.22% 144
2019
Q2 		– Sell
-202,671
Closed -$27.4M – 545
2019
Q1 		$27.4M Buy
+202,671
New +$25.2M 0.36% 90
2017
Q2 		– Sell
-11,924
Closed -$1.45M – 577
2017
Q1 		$1.45M Sell
11,924
-775,569
-98% -$100M 0.01% 416
2016
Q4 		$96.3M Buy
787,493
+325,965
+71% +$39.9M 0.8% 18
2016
Q3 		$56.6M Sell
461,528
-564,242
-55% -$72.6M 0.52% 51
2016
Q2 		$120M Buy
1,025,770
+725,723
+242% +$103M 1.13% 5
2016
Q1 		$41.8M Sell
300,047
-115,990
-28% -$17M 0.38% 89
2015
Q4 		$79.4M Sell
416,037
-23,902
-5% -$4.18M 0.84% 23
2015
Q3 		$68.8M Buy
439,939
+126,453
+40% +$23.1M 0.81% 27
2015
Q2 		$56.7M Buy
313,486
+127,992
+69% +$22.1M 0.64% 29
2015
Q1 		$32.1M Buy
185,494
+32,188
+21% +$5.83M 0.45% 77
2014
Q4 		$28.4M Buy
153,306
+30,929
+25% +$5.73M 0.48% 64
2014
Q3 		$20.3M Sell
122,377
-58,155
-32% -$9.55M 0.42% 78
2014
Q2 		$28.2M Buy
180,532
+83,909
+87% +$13.2M 0.63% 33
2014
Q1 		$14.7M Buy
96,623
+11,623
+14% +$1.85M 0.4% 91
2013
Q4 		$11.3M Buy
+85,000
New +$10.2M 0.45% 79

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Alyeska Investment Group's ALXN Position: Q3 2021 in Review

Alyeska Investment Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 400,000 shares — an estimated $73.5M sold.

Alyeska Investment Group first reported a position in ALXN in Q4 2013 and held it in 18 quarters. The position peaked at $120M in Q2 2016. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Alyeska Investment Group reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Alyeska Investment Group sold 400,000 Alexion Pharmaceuticals shares in Q3 2021, an estimated $73.5M.
  • Alyeska Investment Group first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 18 quarters.
  • Alyeska Investment Group's Alexion Pharmaceuticals position peaked at $120M in Q2 2016.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Alyeska Investment Group's 13F filing for Q3 2021, filed 15 Nov 2021.